CLIN CHEM LAB MED:在健康儿童和青少年的CALIPER队列中确定免疫分析的儿科参考区间

2020-02-04 Gladiator MedSci原创

既往研究表明,儿科实验室检查的诊断实用性在很大程度上取决于可以参考的准确的参考间隔(RI)。

既往研究表明,儿科实验室检查的诊断实用性在很大程度上取决于可以参考的准确的参考间隔(RI)。 加拿大儿科参考间隔实验室倡议(CALIPER)建立了一个协变量分层RI的综合数据库,适用于使用大量健康参考人群的许多儿科实验室检测。 已经研究了在临床实验室中广泛使用的几种自动分析仪。 在这里,我们将测试范围扩展到罗氏免疫测定法,并首次报告了17种内分泌和特殊化学标记物的全面儿科RI

本研究共招募741名健康儿童和青少年(1天至<19),在罗氏cobas 8000 e602免疫分析仪上对血清样本进行免疫分析,建立年龄和性别特异性RIs,并根据临床和实验室标准协会指南计算相应的90%置信区间(CIs)

所有分析物的参考值均按照测量所需的年龄划分,特别是在早期生活和整个青春期。在17个被测分析物中,其中8个进行性别划分,包括铁蛋白、促甲状腺激素(TSH)、总三碘甲状腺氨酸(TT3)以及除催乳素外的所有生育/性激素。

本研究结果是第一个确定准确罗氏免疫测定的儿科RIs的研究。RIsCALIPER之前在其他分析平台上发表的研究结果大体相似,表明了在整个儿科年龄范围内观察到的参考值的年龄和性别特异性趋势的可重复性。本研究建立的RIs将提高临床实验室使用罗氏免疫测定的检测结果解释和临床决策的准确性。

原始出处:

Mary Kathryn BohnVictoria HigginsPaediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928167, encodeId=5657192816e8c, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Oct 07 01:31:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937502, encodeId=ae60193e50243, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 17 02:31:00 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728287, encodeId=007b1e282876d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 13:31:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546917, encodeId=b515154691e3e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610218, encodeId=07281610218a6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928167, encodeId=5657192816e8c, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Oct 07 01:31:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937502, encodeId=ae60193e50243, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 17 02:31:00 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728287, encodeId=007b1e282876d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 13:31:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546917, encodeId=b515154691e3e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610218, encodeId=07281610218a6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928167, encodeId=5657192816e8c, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Oct 07 01:31:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937502, encodeId=ae60193e50243, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 17 02:31:00 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728287, encodeId=007b1e282876d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 13:31:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546917, encodeId=b515154691e3e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610218, encodeId=07281610218a6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
    2020-06-13 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928167, encodeId=5657192816e8c, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Oct 07 01:31:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937502, encodeId=ae60193e50243, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 17 02:31:00 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728287, encodeId=007b1e282876d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 13:31:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546917, encodeId=b515154691e3e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610218, encodeId=07281610218a6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1928167, encodeId=5657192816e8c, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Oct 07 01:31:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937502, encodeId=ae60193e50243, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 17 02:31:00 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728287, encodeId=007b1e282876d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 13:31:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546917, encodeId=b515154691e3e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610218, encodeId=07281610218a6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:31:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]

相关资讯

Stroke:缺血性卒中患者30天再入院的估计!

高达12%的缺血性脑卒中患者在出院30天内再次入院,再通治疗与30天再住院的几率降低11%到23%有关。

Eur Respir J:全球青少年结核病发病率估计!

由此可见,年轻人患肺结核病的负担很重。这个年龄段的年龄特异性疾病负担估计常常存在结核病数据中年龄分类不完整,突出了继续加强监视系统建设的重要性。